ResearcherUniversity of California Davis Medical CenterNo recent work listed
Thomas John Semrad
Matched on ORCID iD 0000-0002-7810-5887; OpenAlex author ID A5016991744. Sources: OpenAlex.
Their work
- Papers
- 2
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper
Papers 2
- A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer. Co-author DOI 10.1007/s00280-022-04457-9↗
- Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Co-author DOI 10.1007/s10147-014-0730-2↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Edward Jae-Hoon Kim · 2 shared papers, 2015–2022 · strength 0.17
- Paper A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumo… DOI 10.1007/s00280-022-04457-9↗
- Paper Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeuti… DOI 10.1007/s10147-014-0730-2↗
- Justin A. Chen · 1 shared paper, 2022 · strength 0.13
- Aiming Yu · 1 shared paper, 2022 · strength 0.13
- Afsaneh Barzi · 1 shared paper, 2015 · strength 0.04
- Heinz‐Josef Lenz · 1 shared paper, 2015 · strength 0.04
- Primo N. Lara · 1 shared paper, 2015 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.